1 Cutaneous resistance arteries (c.r.a.) (internal diameter=240.94+5.42 mm, n=67/25 (number arteries/number animals)) from New Zealand white rabbits were mounted in wire myographs and a normalization procedure followed. 2 Cumulative concentration-response curves (CCRCs) were constructed for the a-adrenoceptor agonists noradrenaline (NA), (R)A61603 and phenylephrine (PE) in the presence of cocaine (3 mM), propranolol (1 mM) and corticosterone (10 mM). The eects of competitive a 1 -adrenoceptor antagonists, prazosin, WB4101, 5-methyl-urapidil, HV723, BMY7378 and the irreversible a 1B selective compound chloroethylclonidine (CEC) were examined versus the potency and maximum response of the c.r.a.s to noradrenaline. 3 The high potency of A-61603 relative to PE has been shown to dierentiate both functional and binding site a 1A -or a 1B -adrenoceptors from a 1D -adrenoceptors: A-61603 was 944 times more potent than phenylephrine (at EC 50 ) suggesting the presence of a functional a 1A or a 1B as opposed to an a 1D -subtype. 4 Exposure to chloroethylclonidine (CEC; 100 mM) decreased the maximum response to noradrenaline but did not signi®cantly change noradrenaline sensitivity indicating that a substantial part of noradrenaline-induced vasoconstriction in rabbit cutaneous arteries is CEC-insensitive. 5 The potencies of prazosin (pA 2 =9.14) and WB4101 (pA 2 =9.30) indicate the involvement of prazosin-sensitive functional a 1 -adrenoceptors. The slopes of corresponding Schild plots for prazosin and WB4101 did not include negative unity which implies the possible involvement of more than one functional a 1 -adrenoceptor subtype in noradrenaline-induced vasoconstriction in rabbit cutaneous resistance arteries. In contrast to this, in the case of 5-methyl-urapidil and HV723, the Schild plot slope parameters were not signi®cantly dierent from negative unity over the range of concentrations used; the low pA 2 value for 5-methylurapidil (7.27) suggests the non-involvement of an a 1A -or an a 1D -adrenoceptor; the low pA 2 value for HV723 (8.47) was similar to that against responses postulated as a 1L . 6 We conclude that rabbit cutaneous resistance arteries express a prazosin-sensitive functional a 1 -adrenoceptor resembling the a 1B and another low anity site for prazosin which on the basis of the functional antagonism produced by HV723 most closely resembles the a 1L -adrenoceptor; the low pA2 value for HV723 (8.47) is similar to that against responses postulated as a 1L .
Introduction a 1 -Adrenoceptors are a heterogeneous group of receptors the subclassi®cation of which is far from resolved. It has long been known that the agonist potency series at a 1 -adrenoceptors varies greatly between tissues (Ruolo, 1985) . The ®rst attempt at subclassifying a 1 -adrenoceptors into a 1a -and a 1b -adrenoceptors was partly based on the variable potency series for agonists in dierent tissues (McGrath, 1982) and, recently, it has been demonstrated that the relative potencies of two agonists, phenylephrine and A-61603 can distinguish between subtypes which have been de®ned by other means (Knepper et al., 1995) . Later subclassi®cation schemes were mainly based on radioligand binding studies, initially of native receptors (Battaglia et al., 1983; Morrow & Creese, 1986 ) and later of recombinant receptors (Schwinn & Lomasney, 1992; Forray et al., 1994) ; there is relatively less information on the subclassi®cation of functional a 1 -adrenoceptors; the present classi®-cation scheme of these receptors remains dominated by sensitivity to prazosin.
Although there is a wide continuum of prazosin potency (Drew, 1985) amongst functional a 1 -adrenoceptors, it has been suggested that they should be subdivided into prazosin-sensitive (high: a 1H ) and prazosin-insensitive (low: a 1L ) subtypes (Flavahan & Vanhoutte, 1986) . Subsequently, when a 1 -adrenoceptors were cloned, the 3 clones, when re-expressed, all showed high sensitivity to prazosin, so that the functional equivalents of those 3 clones termed a 1a , a 1b and a 1d (Bylund et al., 1994) should all be subsets of the a 1H (Muramatsu et al., 1991) .
Prazosin-sensitive functional a 1 -adrenoceptors have been divided into a 1A and a 1B on the basis of WB4101 anity in ligand binding (Morrow & Creese, 1986) ; this can be translated to the functional level, for example, WB4101 can distinguish these subtypes by blocking noradrenaline-induced contraction in rat vas deferens (a 1A , K B =0.3 nM) with higher anity than in rat spleen (a 1B , K B =5.4 nM) (Han et al., 1987) . From this original de®nition with two subtypes, a 1A and a 1B , the a 1A has now been divided, for a number of reasons, into a 1A and a 1D (Bylund et al., 1994) : at the level of functional competitive antagonism this separation is not easy to make, although recently BMY7378 (Goetz et al., 1995) has been postulated as selective for a 1D over a 1A .
Some, but not all,`prazosin-insensitive' a 1L -adrenoceptors have relatively low anity for HV723 (K B =2 ± 7 nM) compared with the prazosin-sensitive sites which have relatively higher anity for this compound (K B =0.4 ± 1 nM); this low anity for HV723 in conjunction with low anity for prazosin is thus a further marker for the a 1L -adrenoceptor (Muramatsu et al., 1990b) .
Despite this complex background, it is important to attempt to establish which a 1 -adrenoceptor subtypes are involved in the control of vascular resistance . For example, currently, there is a controversy over whether a 1 -subtype selectivity will convey selectivity on a 1 -adrenoceptor antagonists in relieving the symptoms of benign prostatic hypertrophy while avoiding hypotensive side eects (Forray et al., 1994) . It has long been known that both a 1 -and a 2 -adrenoceptors produce vasoconstriction in several species, including rat, rabbit and dog (Docherty & McGrath, 1980; McGrath et al., 1982; Alabaster et al., 1985; Guimaraes & Nunes, 1990) . However, few in vitro studies have attempted to classify whether the a 1 -or a 2 -adrenoceptors are involved in mediating vasoconstriction in resistance arteries; some studies have suggested that responses to exogenously applied and neurally released noradrenaline in human subcutaneous resistance arteries are mediated by both a 1 -and a 2 -adrenoceptors (Nielsen et al., 1990; Parkinson et al., 1992) .
Other studies have suggested that vasoconstriction of arterioles and venules is mediated by dierent a-adrenoceptor subtypes (Leech & Faber, 1996) ; vasoconstriction in rat skeletal muscle arterioles being mediated predominantly by an a 1D -like receptor and an a 2D -whereas constriction of venules is dominated by the a 1B -and the a 2D -adrenoceptor subtypes. Van der Graaf et al. have attempted to subclassify the a 1 -adrenoceptors which mediate vasoconstriction in both rat aorta (Van der Graaf et al., 1996a) and rat mesenteric resistance vessels (Van der Graaf et al., 1996b) ; their analysis concluded that there was more than one subtype of functional a 1 -adrenoceptor present in the aorta and that a 1L -adrenoceptors mediated part of the noradrenaline-induced vasoconstriction observed in rat small mesenteric arteries. We have published data which indicate that there are developmental changes in functional a 1 -adrenoceptor subtypes in rat mesenteric resistance arteries (Smith & McGrath, 1996) . These studies indicate that there may be an a-adrenoceptor subtype-speci®c role in the regulation of vascular tone, which could be altered with age and cardiovascular disease and is therefore of relevance to the use of adrenoceptor ligands in treatment of cardiovascular diseases or other pathologies involving tissues modulated by catecholamines.
The aim of this study was to investigate, in vitro, the a 1 -adrenoceptors subtype(s) mediating vasoconstriction of rabbit cutaneous resistance arteries, which preliminary studies had shown to contract to agonists in a potency series consistent with a 1 -but not a 2 -adrenoceptors, i.e., phenylephrine44UK14304 (Macmillan et al., 1994) . To this end we investigated the potency series for the agonists, noradrenaline, phenylephrine and (R)A-61603 and the antagonist potency of the key antagonists prazosin, WB4101, 5-methyl-urapidil, HV723 and BMY7378.
Some of these results have been published in abstract form (Smith et al., 1996) .
Methods

Rabbit cutaneous artery preparation
Experiments were carried out in male New Zealand white rabbits weighing 3.0 ± 3.5 kg. They were killed by an overdose of pentobarbitone into the ear vein and a¯ap of skin from the area overlying the gluteal muscles was removed. Connective tissue was cleared from above the network of cutaneous arteries and resistance arteries (2 mm length) were isolated and excised under a dissecting microscope.
Cutaneous resistance arteries (internal diameter = 240.94+5.42 mm, n=67/25) were mounted as ring preparations in a Mulvany-Halpern double myograph (J, P Trading, Aarhus, Denmark), mounted on two 40 mm steel wires which are attached to a force transducer and a micrometer, as described by Mulvany & Halpern (1977) . The vessel was bathed in Krebs-Henseleit solution (in mM: NaCl 118.4, KCl 4.7, MgSO 4 .H 2 0 1.2, KH 2 PO 4 1.2, NaHCO 3 24.9, CaCl 2 2.5, glucose 11.1, EDTA 0.023), kept at 378C and gassed with 95%O 2 / 5%CO 2 mixture. Additionally, cocaine (3 mM), propranolol (1 mM) and corticosterone (10 mM) were present, in all experiments.
Normalization procedure
After a rest period of 30 min, the artery was stretched at 1 min intervals to determine the exponential passive wall tensioninternal circumference (L) relationship. From the Laplace relationship, where P=T/r (P is the eective pressure, T is wall tension and r is the internal radius), the circumference (L 100 ) was calculated by an iterative computer method that gave an equivalent transmural pressure dierence at 100 mmHg for each artery. The circumference at 0.96L 100 was calculated where the active force production was close to maximum (data not shown). Normalized vessel internal diameter for the remainder of the experiment was set at 0.96L 100 . From the known length-tension relationship we calculated the equivalent wall tension at 0.96L 100 and the equivalent eective pressure P 1 (mmHg). Eective pressure is an estimate of the pressure which would be necessary to extend the vessel to the measured internal circumference. If the arteries had a normalized internal diameter greater than 300 mm, they were excluded from our study.
a 1 -Adrenoceptor agonists
After the normalization procedure, the arteries were exposed to noradrenaline (NA, 10 mM), until equilibrium contraction was established and then washed. Thirty minutes later, a cumulative dose-response curve at half log unit steps was generated to noradrenaline (1 ± 1000 nM), phenylephrine (1 ± 10,000 nM) or (R)A-61603 (0.01 ± 1000 nM) in half log unit concentration increments, in the presence of cocaine (3 mM), propranolol (1 mM) and corticosterone (10 mM). The CRC to noradrenaline was repeated and data derived from the second curve since time-control studies showed that the CRC to NA varied between the ®rst and second CRCs but was consistent in the subsequent CRCs thereafter, up to the ®fth (data not shown).
a 1 -Adrenoceptor antagonists
The procedure followed was essentially the same as in the a 1 -agonist protocol for NA. Five CRCs to NA were constructed. The second curve served as the control and three increasing concentrations of test antagonists were added 30 min before the third to ®fth CRCs: the a 1 -adrenoceptor antagonists used were prazosin, WB4101, HV723, 5-methyl-urapidil and BMY7378. Antagonist potency was expressed as a pA 2 value which was obtained from the x-intercept of the plot of log (agonist DR71) against log (antagonist concentration) (Arunlakshana & Schild, 1959) .
Chloroethylclonidine
After an initial exposure to NA (10 mM), 2 CRCs were constructed to NA; the second of which served as a control; followed by exposure to chloroethylclonidine (10 mM or 100 mM) for 60 min, 30 min of washing with Krebs (106 washes) and a second CRC to NA (O'Rourke et al., 1995; Williams & Clarke, 1995) .
Statistics
Contraction responses were expressed as increase in active effective pressure (P, mmHg), calculated as increase in isometric tension (T) above resting divided by the normalized internal radius. Responses were averaged at each concentration of the agonist. Agonist potency was expressed in terms of a pD 2 value which represents the negative log of the concentration of the agonist required to produce 50% of the maximum response. Antagonist pA 2 values and slopes of Schild regressions were calculated by use of GraphPad Prism Version 2.0 (GraphPad Software Inc., San Diego, CA). Dierences were considered signi®cant at a level of P50.05.
Drugs
The following drugs were used: chloroethylclonidine dihydrochloride (CEC; Research Biochemicals Incorporated (RBI)), cocaine HCl (Macarthys), corticosterone 21-acetate (Sigma), HV723 (a-ethyl-3,4,5-trimethoxy-a-(3-((2-(2-methoxy phenoxyethyl)-amino)-propyl)benzeneacetonitrile fumarate) (gift I. Muramatsu), (7)-noradrenaline bitartrate (Sigma), phenylephrine hydrochloride (Sigma), prazosin hydrochloride (Sigma), propanolol HCl (Sigma), WB4101 (2-(2.6-dimethoxy-
All concentrations of drugs are expressed as a ®nal concentration in the myograph. All drugs were prepared from salts each day in deionized water with the exception of noradrenaline, which was dissolved in 23 mM Na 2 EDTA, and corticosterone, which was dissolved in ethanol.
Results
Noradrenaline produced a concentration-response curve with a pD 2 of 7.06+0.08 (n=53/25) (n=vessels/rabbits) (mean+ s.e.mean, 7log M) and a maximum contraction of 36.42+2.32 mN mm Table 1) .
Prazosin, WB4101, HV723 and 5-methyl-urapidil produced concentration-dependent shifts in the potency of NA without reducing the maximum response over the ranges used for analysis. 5-Methyl-urapidil (100 mM) depressed the maximum and virtually abolished the response and so was not included. Schild plots were constructed from the eects of a range of concentrations of each antagonist and pA 2 values were calculated (Figures 2(a and b), 3(a and b) , 4(a and b) and 5(a and b) and Table 2 ). BMY7378 was tested across the range 0.01, 0.1 and 1 mM in order to cover the range of potency against a 1D -adrenoceptors, but this proved too low to construct a Schild plot. The estimated pK B for BMY7378 with shifts at 0.1 and 1 mM was 7.06+0.21 (n=7/4).
Exposure to the irreversible antagonist CEC (100 mM) decreased the maximum response to NA but did not result in a signi®cant change in noradrenaline sensitivity (NA pD 2 pre-CEC=7.02+0.19 (n=8/4); NA pD 2 post-CEC=6.40+0.57 (n=8/4) ( Figure 6 ). CEC (10 mM) had no eect on either the maximum response or the sensitivity to noradrenaline.
Discussion
In this study, we have examined, for the ®rst time, the subtypes of functional a 1 -adrenoceptors mediating vasoconstriction in rabbit cutaneous resistance arteries, by use of both selective agonists and antagonists. Previous studies have shown that a 1 -adrenoceptors play a role, along with a 2 -adrenoceptors in mediating vasoconstriction in`resistance' arteries from both man and rats (Nielsen et al., 1990; Stephens et al., 1992; Leech & Faber, 1996) .
The main hindrance in the subclassi®cation of functional a 1 -adrenoceptors is the lack of compounds which not only can distinguish dierent subtypes of a 1 -adrenoceptor binding sites but also can reproduce their subtype-selectivity at functional a 1 -adrenoceptors. The agonist potency of A-61603 relative to PE has been shown to dierentiate functional a 1A and a 1B from a 1D -adrenoceptors (Knepper et al., 1995) : A-61603 is a potent agonist at a 1A -adrenoceptors in rat vas deferens (200 to 300 fold more potent than NA or PE, respectively) and in canine isolated prostate strips (130 to 165 fold more potent than NA or PE, respectively). In contrast to this, A-61603 is only 40 fold more potent than PE at a 1B sites in rat spleen and is 35 fold less potent at rat aortic a 1D sites.
According to this hypothesis, the relative potency of (R)A-61603 to PE in rabbit cutaneous resistance arteries (see Table  1 ) indicates the involvement of the a 1A -or a 1B -adrenoceptor subtypes in vasoconstriction, as opposed to the a 1D subtypes, although the resulting, very high, PE/(R)A61603 potency ratio is outwith the range for even the a 1A -subtype. This may be due to our use of the more potent (R) enantiomer as opposed to the The values represent the potencies (EC 50 61nM) of A-61603, phenylephrine (PE) and noradrenaline (NA) in cutaneous resistance arteries compared with their potencies in other functional studies (reproduced from Knepper et al., 1995) . *Represents the R enantiomer of A-61603. racemic compound. It should also be noted that all three agonists were very much more potent on rabbit c.r.a. than on the tissues used as examples of a 1A -and a 1B -subtype. We know of no data on the eects of (R)-A61603 at examples of a 1L . The high potency of (R)A-61603 may be due to it having a high potency at the a 1L -adrenoceptors; previously some authors have suggested that a 1L -adrenoceptors mediate noradrenalineinduced vasoconstriction in rat vas deferens . If it is concluded from the present study that a 1L -adrenoceptors are involved in rabbit c.r.a. then these receptors also may be sensitive to this agonist. Contractions to NA were potently inhibited by prazosin, WB4101, HV723 and 5-methyl-urapidil, without signi®cantly aecting the maximum response to NA. Analysis of the Schild plots for prazosin and WB4101 indicated that the resulting slopes did not include negative unity, their values suggesting the possible involvement of more than one a 1 -adrenoceptor type (Kenakin, 1982) . This is re¯ected in the non-parallel shift in the lowest part of the CRC, evident in Figures 2(a) and 3(a) .
The potencies of prazosin (prazosin 1 nM; pK B = 9.28+0.07) and WB4101 (WB4101 1 nM: pK B =9.23+0.03) suggest the presence of a`high anity for prazosin' a 1 -adrenoceptor subtype; the high anity for WB4101 might suggest an a 1A -subtype. However, the resulting low slopes from their Schild plots suggest the involvement of an additional low prazosin-anity a 1 -subtype. Evidence for this is provided by the estimated pK B values derived for the higher concentrations of prazosin and WB4101, which point to lower anities than either the pK B estimated from the lowest antagonist concentrations or the extrapolated pA 2 values, which take all antagonist concentrations into account. This focuses attention on the eects of the lowest concentrations of prazosin and WB4101, which, essentially, were more eective than would be expected from the eects of higher concentrations and suggest that, at low concentrations (1 nM), these two antagonists may be identifying a receptor for which they have high anity and which accounts for the response to the lowest concentrations of noradrenaline. A corollary of this is that the response which remains to NA in the presence of low concentrations of prazosin and WB4101 is more resistant to blockade, i.e. has lower anity for prazosin and WB4101, suggesting that NA is acting through this receptor at a higher concentration range. Taking all this into account, the low absolute potency of HV723 (pA 2 =8.47) relative to prazosin and WB4101 supports the presence of a functional a 1L -adrenoceptor, as de®ned by Muramatsu et al. (1990b) .
The low potency of 5-methyl-urapidil (pA 2 =7.27) and the substantial shift in NA maximum response produced by preexposure to chloroethylclonidine (Figure 6 ) argue against the classi®cation of the high prazosin-anity site as an a 1A subtype.
The Schild plots, close to unity, of 5-methyl-urapidil and HV723 suggest that neither of these compounds distinguishes Table 2 ). Table 2 ). Table 2 ). Table 2 ). two subtypes. From the literature, in studies of functional a 1 -adrenoceptor subtypes, 5-methyl-urapidil is unable to distinguish between the a 1B -and the a 1L -subtypes, having similar potencies at both the human internal iliac artery (a 1B -) (pA 2 =7.43+0.22; Hatano et al., 1994) and the rabbit prostate (a 1L -) (pA 2 =7.87+0.08; Hiraoka et al., 1995) . It is also evident from the literature that HV723 has similar anities at both the a 1L -of rabbit prostate (pK i =8.36+0.07; Hiraoka et al., 1995) and the a 1B -subtype of rat liver (pK i =8.88+0.05; Ohmura & Muramatsu, 1996) . Hence, their Schild slopes, which include negative unity, implying competitive antagonism at a single receptor site, are also consistent with two sites at which they have similar anity, re¯ecting the inability of 5-methyl-urapidil or HV723 to distinguish between a 1B -and a 1L -adrenoceptor subtypes. If their absolute values for pA 2 s are compared with the literature, then both appear low, which would also indicate a 1B -receptors identi®ed by 5-methyl-urapidil and a 1L -receptors identi®ed by HV723.
The pA 2 for 5-methyl-urapidil in rabbit cutaneous arteries in our study (7.27 ) is similar to the pK B which Leech and Faber (1996) obtained for the same drug in rat (cremaster) skeletal muscle arterioles (7.35+0.11). Our pA 2 for WB4101 is a little higher (9.26) than the pK B estimated by Leech and Faber (8.82+0.14) . However, they derived anity from single concentrations rather than a range of concentrations of antagonists. With WB4101 10 nM, the concentration used by Leech & Faber, we obtained an identical pK B to theirs (8.83+0.11). The anity of the a 1D -selective compound, BMY7378 is also similar between the two studies; its apparent dissociation constant (pK B ) at rat skeletal arterioles was 6.86+0.25, which is similar to its anity in our study of rabbit cutaneous resistance arteries (pK B =7.06+0.21). Leech and Faber concluded that rat skeletal arterioles contain the a 1D -adrenoceptors, based on the supposition that the relatively high anity of WB4101 was more important than the very low apparent anity of BMY7378, which would be expected to have an anity of *1 nM at functional a 1D -adrenoceptors (Piascik et al., 1995) . In the light of this, the low anity of BMY7378 from our study, supported by the agonist series, argues against the involvement of a 1D -adrenoceptors in noradrenaline-induced vasoconstriction in rabbit cutaneous resistance arteries; perhaps the rat cremaster arterioles are similar.
The reduction of the noradrenaline maximum by chloroethylclonidine (100 mM), without any shift in sensitivity, could be taken as evidence of two receptor subtypes, one sensitive and one insensitive to this compound, presumably the sensitive Table 2 were used; BMY7378 is used at 1 mM. The comparator tissues have been characterized as containing functional a 1A -(rat vas deferens, rat caudal artery), a 1B -(rat spleen, human internal iliac artery, dog vertebral and carotid arteries), a 1D -(rat aorta) or a 1L -(dog femoral artery and femoral vein, rabbit mesenteric artery, thoracic aorta, carotid artery and guinea pig thoracic aorta) adrenoceptors (Aboud et al., 1993; Feng et al., 1996; Hatano et al., 1994; Kenny et al., 1995; Kohno et al., 1994; Lachnit et al., 1997; Muramatsu et al., 1990a; Muramatsu et al., 1990b) . Values are mean+s.e.mean and r represents the correlation coecient. Data was not available in the literature for HV723 versus a 1D or BMY7378 versus a 1L . The dashed line indicates the line of identity in each correlation.
one being hypothetically a 1B , and their responses being additive. We ®nd it dicult to place much weight on this observation but include it since this compound is commonly employed in a 1B -adrenoceptor classi®cation.
We have plotted correlations of the ranges of potencies (pK) of prazosin, WB4101, HV723 and 5-methyl-urapidil from rabbit cutaneous resistance arteries against potencies of these same antagonists taken from the literature at functional a 1 -adrenoceptor subtypes in tissues which have been characterized, by the authors, as containing a 1A -, a 1B -, a 1D -or a 1L -adrenoceptors. By use of pK B values resulting from low concentrations of prazosin (1 nM) and WB4101 (1 nM), our data produce reasonably linear correlations with the a 1A -(r=0.80), a 1B -(r=0.93), a 1D -(r=0.87) and a 1L -subtypes (r=0.96). However, the plot resembled the line of equal values most closely for a 1B - (Figure 7a ). Correlation analysis with the higher concentrations of prazosin (100 nM) and WB4101 (100 nM) also resulted in a good linear correlation with a 1L -(r=0.91), a 1D -(r=0.87) and a 1B -(r=0.90) but a lower correlation with the a 1A -subtype (r=0.81). In this case the values again lay close to equality against a 1B -, with the exception of prazosin (which was lower in rabbit c.r.a.) but also showed equality with a 1L -, with the exception of 5-methyl-urapidil (which was lower in rabbit c.r.a.) (Figure 7b ). Taken together this tends to reinforce the hypothesis of two functional subtypes of a 1 -adrenoceptor in these resistance arteries, or at least to suggest that it is dicult to distinguish between a 1B -and a 1L -subtypes.
We suggest that the simplest interpretation of our data, on the basis of the current, antagonist-based subclassi®cation of functional a 1 -adrenoceptors, is that rabbit cutaneous resistance arteries express a prazosin-sensitive a 1 -adrenoceptor subtype, unlikely to be an a 1D , most probably the a 1B -subtype and, also, an a 1L -subtype, both of which are involved in mediating vasoconstriction. However, it should be borne in mind that the agonist data suggest a 1A -and that the distinction between a 1A -and a 1B -is heavily dependent on the low anity for 5-methylurapidil, a compound which has a very variable eect.
